Background:

Ropivacaine hydrochloride monohydrate is an effective, long-acting and local anaesthetic [1].

In COS-7 cells, Ropivacaine hydrochloride monohydrate has been reported to inhibit the the SUR2A/Kir6.2 channel currents. The inhibitory effects of Ropivacaine have shown be concentration-dependent and reversible because the channel currents recovered after washout. Furthermore, the IC50 values of Ropivacaine hydrochloride monohydrate are 249±11, 2235±115, 2442±132 and 2375±179μM for SUR2A/Kir6.2, SUR2B/Kir6.1, SUR2B/Kir6.2 and Kir6.2△C36, respectively. Apart from these, Ropivacaine hydrochloride monohydrate has also demonstrated to inhibit sarcolemmal KATP channels in the cardiovascular system by a stereoselective and tissue-specific way[2].

参考文献:
[1] Reiz S1, H?ggmark S, Johansson G, Nath S. Cardiotoxicity of ropivacaine--a new amide local anaesthetic agent. Acta Anaesthesiol Scand. 1989 Feb;33(2):93-8.
[2] Kawano T1, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y. Molecular mechanisms of the inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on sarcolemmal adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Anesthesiology. 2004 Aug;101(2):390-8.